The Hydroponics Company Ltd (ASX:THC) has entered its first partnership with Sinapse Pty Ltd as a key partner in its strategy to facilitate medicinal cannabis prescribing and dispensing in Australia.
The Hydroponics Company, via its wholly owned subsidiary Canndeo, aims to provide workable solutions to the highly regulated market.
The agreement with Sinapse provides access to more than 9,300 prescribers and pharmacies, streamlining operating efficiencies and process for accessing medicinal cannabis
Dr Andrew Beehag, chief executive officer for Canndeo, commented:
"Streamlining the prescribing and dispensing processes, and significantly reducing the administrative burden on doctors and pharmacists, is a key challenge for prescribing medicinal cannabis.
"I am very impressed with the innovation shown in Australia’s pharmacy sector, and that Sinapse has an ideal solution to the challenges of efficient delivery of medicinal cannabis to Australia’s patients."
The Medicinal Cannabis Medicines Portal
The Medicinal Cannabis Medicines Portal (MCMP) is set to be launched in the December quarter 2017 together with Canndeo, and other foundation medicinal cannabis company participants.
The portal is anticipated to greatly streamline medicinal cannabis access for patients and support health professionals to be compliant with Commonwealth / State / Territory regulatory requirements.
Canndeo will use MCMP for facilitated prescribing and dispensing of its medicinal cannabis products in Australia.